ANAVEX LIFE SCIENCES CORP. (AVXL) Stock Price, Financials & Summary

Price chart

Sep 21Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20

Key dataOct 20, 2026

Open$1.25

From 52W high−85.47%

Volume1.65M

Market cap$126.07M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 20, 2026

Open

$1.25

From 52W high

−85.47%

Volume

1.65M

Market cap

$126.07M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.4x

P/E (TTM)

—

RSI (14)

25.6

MomentumView details →

1D Return

+8.80%

YTD Return

−61.10%

SummaryUpdated Jun 1, 2026

Anavex Life Sciences Corp. (NASDAQ:AVXL) is a clinical-stage biopharmaceutical company founded in 2004 and headquartered in New York. The company has been publicly traded since 2006 and focuses exclusively on developing treatments for central nervous system (CNS) diseases, particularly neurodegenerative and neuropsychiatric conditions. Anavex has built its pipeline around sigma receptor modulators, with its lead drug candidate <b>blarcamesine</b> (ANAVEX 2-73) currently in Phase III trials for Alzheimer's disease and having recently received marketing authorization application acceptance from the European Medicines Agency.

Ask drillr about ANAVEX LIFE SCIENCES CORP. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.1x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−21.38%

ROA (TTM)

−20.01%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+54.14%

FCF YoY

+9.08%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−3.85%

EBITDA YoY

+58.10%

MomentumView details →

1D Return

+8.80%

YTD Return

−61.10%

1Y Return

−85.19%

RSI (14)

25.6

vs 50D SMA

−43.74%

vs 200D SMA

−56.88%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

15.62x

Quick Ratio

15.62x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.03

EPS Surprise

62.50%

Beats (12Q)

7/12

Next Q EPS Est

−$0.12

Avg Surprise (4Q)

13.70%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−24.04M

Op. CF (TTM)

−33.73M

Next earningsNov 24, 2026 →

Latest newsMore news →

A class action lawsuit alleging securities-law violations was filed against ANAVEX LIFE SCIENCES CORP.9d ago

Similar companies

Moleculin Biotech, Inc.MBRX Outlook Therapeutics, Inc.OTLK Nkarta, Inc.NKTX Cue Biopharma, Inc.CUE Tiziana Life Sciences LtdTLSA Minerva Neurosciences, Inc.NERV Find similar companies →

Latest newsMore news →

The U.S. Food and Drug Administration cleared Anavex Life Sciences' investigational new drug application for blarcamesine in Fragile X syndrome, allowing the company to proceed with a planned Phase 2a study in adult males.5d ago A class action lawsuit alleging securities-law violations was filed against ANAVEX LIFE SCIENCES CORP.9d ago A lawsuit involving ANAVEX LIFE SCIENCES CORP. has a lead plaintiff deadline of November 30, 2026.12d ago